|
|
|
Please Note: Press Releases are in Adobe .pdf
format.
To view these documents requires the use
of Adobe
Acrobat Reader, available for free.
2007
Tapestry Receives Notice Regarding Minimum Bid Price Rule
December 21, 2007
Eric Rowinsky, M.D. and Martin Cannon Join Tapestry Board of Directors
December 5, 2007
Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data from its Phase 2 Prostate Cancer Trial
November 5, 2007
Tapestry Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
October 29, 2007
Tapestry to Host Conference Call on November 5th to Discuss Third Quarter 2007 Financial Results
October 29, 2007
Tapestry Announces Strategy to Focus on TPI 287 Clinical Program
October 26, 2007
Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 23, 2007
Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer
October 3, 2007
Tapestry Reports Second Quarter 2007 Results
August 9, 2007
Tapestry to Host Conference Call on August 9th to Discuss Second Quarter 2007 Financial Results
August 2, 2007
Tapestry Pharmaceuticals Withdraws Registration Statement for Public Offering
June 12, 2007
Tapestry Pharmaceuticals to Present at the Needham & Company Biotechnology and Medical Technology Conference
June 7, 2007
Tapestry Pharmaceuticals Presents Phase I Data on TPI 287 at the 43rd ASCO Annual Meeting
June 3, 2007
Tapestry Pharmaceuticals to Present at the Banc of America 2007 Health Care Conference
May 29, 2007
Tapestry Pharmaceuticals to Present Data on TPI 287 at the 43rd ASCO Annual Meeting
May 14, 2007
Tapestry Pharmaceuticals Announces Phase II Clinical Program for TPI 287
May 9, 2007
Tapestry Reports First Quarter 2007 Results
May 9, 2007
Tapestry Pharmaceuticals to Present at the Acumen BioFion Rodman & Renshaw 4th Annual Global Healthcare Conference
May 8, 2007
Tapestry Pharmaceuticals to Webcast Conference Call Discussing First Quarter 2007 Financial Results on May 9, 2007
May 3, 2007
Tapestry Pharmaceuticals Files Registration Statement with the Securities and Exchange Commission
April 23, 2007
Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR Annual Meeting 2007
April 15, 2007
Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting
March 14, 2007
Tapestry Reports Fourth Quarter and Full Year 2006 Results
March 6, 2007
Tapestry Pharmaceuticals to Webcast Conference Call Discussing Fourth Quarter and 2006 Year End Financial Results on March 6, 2007
February 28, 2007
Tapestry Pharmaceuticals appoints Sandra L. Silberman, M.D., PH.D. as Chief Medical Officer
February 20, 2007
2006
Tapestry Pharmaceuticals Appoints Donald H. Picker, Ph.D. as President
December 27, 2006
Tapestry Reports Third Quarter 2006 Financial Results
November 6, 2006
Tapestry to Present at the Rodman & Renshaw 8th Annual Healthcare Conference on Tuesday, November 7th
November 6, 2006
Tapestry to Present at the C. E. Unterberg, Towbin Life Sciences Conference
October 30, 2006
Tapestry Reports Second Quarter 2006 Financial Results
August 8, 2006
Tapestry Pharmaceuticals to Present at 17th Annual Analyst Conference on Wednesday, June 14th
June 13, 2006
Tapestry Reports First Quarter 2006 Financial Results
May 10, 2006
Tapestry Pharmaceuticals Raises $25.5 Million in Private Placement
April 6, 2006
Tapestry Announces Receipt of Going Concern Qualification in Fiscal Year 2005 Audit Report
March 2, 2006
Tapestry Reports Fourth Quarter and Full Year 2005 Results
February 23, 2006
Tapestry Files Proxy Statement Related to Announced Financing
February 10, 2006
Tapestry Signs Agreement for $25.5 Million Financing to Support Clinical Development of TPI 287
February 2, 2006
Tapestry Initiates Second Phase I Clinical Trial for TPI 287
January 10, 2006
2005
Tapestry Presents Data Characterizing its Novel Third Generation Taxane, TPI 287, at AACR/NCI/EORTC Cancer Meeting
November 16, 2005
Tapestry Pharmaceuticals, Inc. to Webcast Presentation at Rodman & Renshaw’s Techvest 7th Annual Healthcare Conference
November 3, 2005
Tapestry Reports Third Quarter 2005 Financial Results
November 2, 2005
Tapestry Webcast Presentation on Lead Oncology Compound, TPI 287
September 13, 2005
Tapestry Pharmaceuticals Mourns the Passing of its Founder Dr. Sterling K. Ainsworth
August 18, 2005
Tapestry Reports Second Quarter 2005 Financial Results
August 3, 2005
Tapestry to Downsize and Focus on TPI 287 Clinical Program
July 25, 2005
Tapestry Initiates Dosing of Phase I Clinical Trial for TPI 287
May 23, 2005
Tapestry Reports First Quarter 2005 Financial Results
May 4, 2005
Tapestry to Present at the Rodman & Renshaw Techvest 2ND Annual Global Healthcare Conference
April 27, 2005
Tapestry Presents Preclinical Data at the American Association for Cancer Research
April 18, 2005
Tapestry to Present at the White Mountain Capital Conference
April 12, 2005
Tapestry to Present at Leerink Swann/MEDACorp Inaugural Health Care Conference
February 28, 2005
Tapestry to Present at the Wells Fargo Securities Health Care Conference
February 23, 2005
Tapestry Reports Fourth Quarter and Full Year 2004 Results
February 23, 2005
Tapestry to Present at the Brean Murray & CO. Annual Institutional Investor Conference
January 27, 2005
Tapestry Free to Proceed with Phase I Trial for TPI 287
January 24, 2005
2004
Tapestry Submits IND for Novel Taxane TPI 287
December 22, 2004
Tapestry Names Elliot Maza to Board of Directors
December 17, 2004
Tapestry on Track to File IND for Novel Taxane
December 6, 2004
Tapestry Pharmaceuticals Announces Plan to Discontinue Gene Editing Operations
November 17, 2004
Tapestry Reports Third Quarter 2004 Results
November 4, 2004
Tapestry Pharmaceuticals to Webcast Presentation at Rodman & Renshaw 6th Annual Techvest Conference
October 21, 2004
Tapestry Announces TPI-273 Shows Potent Growth Inhibition in Multiple Drug Resistant Cell Lines
October 1, 2004
Tapestry Initiating Second in Vivo Preclinical Dose Response Study for Huntington's Disease
September 30, 2004
Tapestry Reports Second Quarter 2004 Results
August 5, 2004
Tapestry Pharmaceuticals, Inc. and Supratek Pharma Inc. Announce Cancer Therapeutics Collaboration
July 22, 2004
Tapestry to Receive $3 Million in Settlement of Paclitaxel Litigation with Mylan Laboratories
July 6, 2004
ASCO Publishes Tapestry Data Highlighting Potential of NBT-287 in Paclitaxel-Resistant Tumors
June 7, 2004
Tapestry (Formerly NaPro BioTherapeutics) Reports First Quarter 2004 Results
May 6, 2004
Tapestry Pharmaceuticals to Present at the Rodman & Renshaw Techvest Global Healthcare Conference
May 5, 2004
NaPro Changes Name to Tapestry Pharmaceuticals
May 4, 2004
NaPro Announces Formation of Oncology Scientific Advisory Board
April 27, 2004
NaPro Announces Formation of Chemistry Advisory Board
April 22, 2004
NaPro Announces the Sale of Two Million Common Shares
March 25, 2004
NaPro BioTherapeutics to Present at the Wells Fargo Securities Health Care Conference
March 22, 2004
NaPro Reports Fourth Quarter and Full-Year 2003 Results
March 11, 2004
Stephen K. Carter, M.D. Joins NaPro Board of Directors
March 10, 2004
NaPro Announces Additions to Scientific Advisory Board
January 12, 2004
|
|
|
